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Background
Human immunodeficiency virus (HIV) is a lentivirus that 
targets CD4+ cells in vivo, including a subset of lympho­
cytes (CD4+ T cells) and a broad range of mononuclear 
phagocytes, including monocytes, dendritic cells, tissue 
macrophages  and  brain  microglia.  The  destruction  of 
CD4+  T  cells  and  immune  dysfunction  results  in  a 
progressive immunodeficiency called acquired immuno­
deficiency  syndrome  (AIDS),  which  in  the  absence  of 
treatment  leads  to  opportunistic  infections  and  malig­
nancies  [1].  Although  immune  system  disorders  have 
been  focused  on  the  most,  HIV  infection  also  has 
significant effects on the central nervous system (CNS), 
as the virus both infects and affects the brain [2]. The 
associated  neuropsychopathology  or  CNS  dysfunction 
then leads to a group of cognitive and behavioral changes 
now  termed  HIV­1­associated  neurocognitive  disorders 
(HAND) or neuroAIDS. NeuroAIDS encompasses a broad 
range  of  neurological  abnormalities,  including  asympto­
matic  neurocognitive  impairment,  HIV­associated  mild 
cognitive  motor  disorder  and  the  most  severe  disease, 
HIV­1­associated dementia (HAD) [3].
The advent of combined antiretroviral therapy (cART; 
previously  referred  to  as  highly  active  antiretroviral 
therapy, HAART), however, has significantly changed the 
dynamics of HIV neuropathogenesis [4]. Severe dementia 
now affects less than 7% of infected people during the 
latter stages of disease. Because of the increasing longe­
vity of HIV­1­infected individuals, the incidence of HAD, 
as well as the other cognitive and motor abnormalities 
associated with HIV­1 infection, has declined, although 
the overall prevalence of neuroAIDS has increased [1,3,5­7]. 
The most severe cognitive, motor and behavioral impair­
ments  are  now  supplanted  by  milder,  less  profound 
cognitive impairment that can nevertheless cause signifi­
cant problems in individuals’ daily lives [8]. HIV­related 
CNS  disease  is  no  longer  a  result  of  continuous 
productive viral infection and activation of brain macro­
phages and microglia, but rather a result of more limited 
infection  and  neuroinflammation  [9].  Although  wide­
spread  use  of  cART  in  places  where  resources  are 
sufficient has increased life expectancy for virus­infected 
individuals,  with  a  concomitant  decrease  in  disease 
morbidities [10,11], neurological complications continue 
to persist. This may be attributed to viral mutation and 
cART  resistance,  failure  of  drugs  to  access  viral  sanc­
tuaries,  toxicities  of  cART  and  poor  compliance  to 
complex cART regimens [12­15]. Abuse of illegal drugs 
[16] and lack of cART availability [17] may also influence 
neurological  disease  manifestations.  Many  aspects  of 
neuroAIDS  pathogenesis  are  well  covered  in  recent 
reviews [18,19].
Early in the course of infection, HIV enters the CNS 
and  remains  detectable  throughout  the  course  of 
infection.  Although  HIV  does  not  infect  neurons,  it 
attacks the monocytic lineage in the brain: macrophages 
and  microglia  [20­23].  The  neurotoxicity  arising  from 
HIV infection therefore results from an indirect mecha­
nism,  possibly  involving  toxic  viral  proteins  or  inflam­
matory  mediators  produced  by  activated  macrophages 
and microglia [24­28], as well as the adaptive immune 
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© 2010 BioMed Central Ltdresponse  to  the  virus  in  the  brain  [29,30].  Although 
studies on the brain can be problematic in humans, an 
excellent animal model, simian immunodeficiency virus 
(SIV) infection of nonhuman primates, recapitulates well 
many aspects of HIV pathogenesis, including neuroAIDS 
[31­35].
A critical gap in the field of neuroAIDS research is the 
identification of reliable molecular markers; these could 
provide valuable insights into the mechanisms of neuro­
pathogenesis and response to therapies, and they could 
aid  in  the  prediction  of  development  of  disease. 
Biomarkers are biological parameters that are objectively 
measured and quantifiable and that indicate changes in 
physiological  states  due  to  pathogenic  processes  or 
therapeutic intervention. In addition to being invaluable 
clinically,  they  have  an  increasingly  prominent  role  in 
drug development and medical research [36,37].
Despite substantive research efforts, the mechanisms 
underlying  cognitive  impairment  resulting  from  HIV 
infection are far from understood. However, the advent 
of high­throughput strategies such as genomics, trans­
criptomics,  proteomics  and  metabolomics  has  revolu­
tion  ized  biological  investigations  and  brought  great 
insights. This especially holds true for mass spectrometry 
(MS)­based proteomics and metabolomics, which have 
generated immense interest and which offer different but 
complementary insights into the full complexity of the 
disease phenotype. In addition to allowing the unbiased 
identification  of  molecular  markers  for  disease  states, 
these approaches also enable a greater understanding of 
the processes underlying them.
Neuroproteomics and biofluids profiling
Cerebrospinal fluid biomarkers for neuroAIDS
Neuroproteomics  reveals  complex  protein  expression, 
function,  interactions  and  localization  in  cells  of  the 
nervous system. Although ideally one would analyze the 
brain  itself,  obtaining  brain  biopsy  specimens  is  not 
usually practical. Profiling of biofluids is therefore ideal, 
and  the  relative  ease  of  obtaining  data  from  the  same 
animals or people over time also means that longitudinal 
molecular  analyses  of  changes  during  the  course  of 
neuro  logical diseases can be conducted. Of the biofluids, 
the  cerebrospinal  fluid  (CSF)  is  close  to  the  site  of 
neuropathology and can reflect the biochemical milieu of 
the CNS. There is a growing consensus that the CSF is 
the best material for biomarker discovery and for under­
standing the ongoing pathological processes associated 
with neurodegeneration [38,39]. The protein component 
of CSF consists of brain­derived proteins as well as many 
proteins  that  are  also  abundant  in  plasma  [40].  The 
complexity and great dynamic range of protein concen­
trations as well as protein heterogeneity in the CSF create 
significant  challenges  to  the  existing  proteomic 
technologies [41]. To address these challenges (which are 
not unique for CSF and also apply to blood­based tests 
on plasma and serum), advances have been made on two 
fronts:  enrichment  of  potential  proteins  of  interest 
expressed  at  lower  levels  by  immunodepletion  of 
abundant  proteins  [42],  and  an  improved  ability  to 
separate  the  great  number  of  peptides  resulting  from 
protein  digestion  using  multi­dimensional  chromato­
graphy before MS [43].
One recent study used immunodepletion followed by 
two­dimensional difference gel electrophoresis (2D­DIGE) 
to identify differentially expressed features and then MS 
to  identify  the  proteins  that  differentiated  individuals 
with HAD from HIV­infected individuals without CNS 
disease [44]. This method required a certain amount of 
protein,  because  of  which  only  6  of  the  38  available 
samples (16%) could be assessed. Nevertheless, this study 
was  successful  in  identifying  six  putative  bio  markers: 
vitamin  D  binding  protein,  clusterin,  gelsolin,  comple­
ment C3, procollagen C­endopeptidase enhancer 1 and 
cystatin  C.  Of  these,  vitamin  D  binding  protein  was 
upregulated  and  the  other  five  proteins  were  down­
regulated in the CSF of HAD patients.
A separate study from our lab [45] used a more stream­
lined  approach  to  identify  differentially  expressed 
proteins in the CSF of SIV­infected monkeys, comparing 
the  CSF  from  the  same  animals  before  infection  and 
during CNS disease. This technique bypassed immuno­
depletion or other manipulations and used small amounts 
of  protein  isolated  by  organic  extraction  followed  by 
limited pre­fractionation using a liquid chromatography 
tandem MS (LC­MS/MS) approach. Among the proteins 
differentially  expressed  in  the  SIV­infected  monkeys, 
complement  C3  was  identified  but  found  to  be  up­
regulated in the CSF of infected monkeys. The difference 
between  the  two  studies  [44,45]  can  be  attributed  to 
numerous factors, including looking at a human disease 
or a monkey model, the different sites of CSF removal, 
the study designs and other aspects of experimentation.
We also investigated [45] whether the increase in C3 
reflected  synthesis  in  the  brain  or  leakage  across  the 
blood­brain barrier. Quantitative real­time PCR revealed 
that the mRNA level of C3 was indeed increased in the 
brains  of  diseased  animals.  This  increase  corroborates 
other studies in which an increase in C3 in astrocytes, 
microglia and, to a lesser extent, neurons was found in 
SIV encephalitis (SIVE) [46]. Furthermore, increased C3 
has been found in other human CNS disorders, including 
Alzheimer’s  disease  and  multiple  sclerosis  [47].  The 
enhanced  complement  synthesis  may  reflect  immune 
activa  tion  in  the  brain,  leading  to  the  formation  of 
molecules  such  as  the  anaphylatoxins  C3a  and  C5a, 
which act as chemoattractants and activators of macro­
phages and microglia and may act through these cells or 
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the brain. Thus, in the case of SIVE, increased C3 probably 
contributes to SIV­induced damage to the brain.
Two  studies  have  used  surface  enhanced  laser 
desorption  ionization  (SELDI)  to  examine  the  CSF.  In 
one, nine proteins were identified uniquely in the CSF of 
individuals  with  HIV­associated  cognitive  impairment 
[55].  These  included  soluble  superoxide  dismutase 
(SOD1),  for  which  western  blot  analysis  verified  its 
increase. SOD1 is an antioxidant and migration inhibi­
tory factor secreted by macrophages during inflammation 
and  an  inhibitor  of  the  protein  kinases  that  are  up­
regulated  in  the  CSF  of  individuals  with  cognitive 
impairment.
The  other  recent  study  also  used  SELDI  to  identify 
increases in chitinase 3­like 1 (CHI3L1, also known as 
HCgp39 and YKL­40) in the CSF as a biomarker of SIVE/
HIV  encephalitis  (HIVE)  [56].  Microglia  and  macro­
phages  were  found  to  produce  CHI3L1.  It  displaced 
extracellular matrix­bound basic fibroblast growth factor 
and inhibited the mitogenic activity of its receptor. This 
may  contribute  to  neurodegeneration  through  lack  of 
ability of this growth factor, and possibly other factors 
bound to the extracellular matrix, to support neurons. 
Independent  studies  corroborate  its  upregulation.  Our 
previous  microarray  studies  of  SIVE  found  increased 
levels of CHI3L1 mRNA in the brain [57], and in our CSF 
proteomics study [45] this protein was elevated in SIVE.
Proteomics has also been used to identify modifications 
of proteins in the CSF, providing clues to the pathogenesis 
of neuroAIDS; in particular, nitrosative/oxidative stress 
has been examined [58]. Levels of proteins modified by 
nitric  oxide,  nitrate  and  3­nitrotyrosine  (3­NT)  were 
assessed  in  the  CSF  of  46  patients  with  HIV  infection 
classified  according  to  their  neurocognitive  status  and 
whether they had a history of intravenous drug abuse. 
Although the levels of nitrates and nitrites were increased 
in individuals with HAD and a history of drug abuse, this 
did  not  reach  significance.  However,  CSF  from  these 
individuals  had  significantly  elevated  levels  of  3­NT­
modified proteins [58]. Subsequent analysis by immuno­
precipitation  and  LC­MS/MS  identified  lipocalin­type 
prostaglandin D synthase (L­PDGS), an enzyme involved 
in the prostaglandin biosynthesis pathway, to be one of 
the major 3­NT­modified proteins in the CSF of HAD 
individuals with a history of drug abuse. Prostaglandins, 
which regulate many physiological functions, have been 
suggested  to  be  involved  in  the  pathogenesis  of  HAD 
[59]. Further analysis by immunoassay revealed a signifi­
cant  reduction  in  the  enzymatic  activity  of  L­PDGS,  a 
reduction  that  was  due  to  3­NT  modification.  This 
correlation  with  HAD  may  be  functionally  important, 
suggesting  that  L­PDGS  is  a  potential  biomarker  for 
neuroAIDS in this population.
Plasma biomarkers for neuroAIDS
Although CSF is ideal for neuroproteomics, its relative 
unavailability  and  the  limited  amount  of  protein  it 
contains makes such studies difficult . By contrast, blood 
plasma  is  a  much  more  accessible  biofluid  and  can 
contain markers relevant for prediction, diagnosis and/or 
further  investigation  into  the  cause  and  effects  of 
neurological  disorders.  Despite  the  ease  of  obtaining 
plasma, a major challenge associated with its analysis is 
that it has a highly complex proteome, similar to that of 
CSF. The relatively high expression of abundant proteins 
such  as  serum  albumin  and  immunoglobulins,  which 
together constitute more than 85% of the total protein 
content, masks the less abundant proteins, which could 
be biomarkers.
Another  necessary  and  informative  step  in  protein 
biomarker discovery is to detect quantitative alterations 
of a protein in different disease and control conditions. 
Development of new quantitative proteomics approaches 
has  greatly  enhanced  proteomics  technologies.  One  of 
these, already mentioned above, relies on identifying the 
different  levels  of  intact  proteins  separated  by  electro­
phoresis  followed  by  protein  identification  by  MS.  An 
alternative strategy is to identify all proteins in a sample 
by  MS  and  use  data  from  the  MS  for  quantification. 
Label­free methods such as used in [45] are possible, but 
chemical reactions to introduce isotopic tags at specific 
functional groups on amino acids have also been found 
to provide excellent methods of quantification. One such 
method is known as isobaric tag for relative and absolute 
quantitation  (iTRAQ)  [60].  In  an  iTRAQ  experiment, 
different samples from control and experimental groups 
are labeled with different tags and up to eight conditions 
can be assessed simultaneously.
Using  such  a  platform,  afamin,  a  member  of  the 
albumin  superfamily  [61],  was  recently  found  by  our 
group to be significantly downregulated after SIV infec­
tion  only  when  CNS  disease  was  developing  [62]. 
Another study using 2D­DIGE­based MS [63] also found 
afamin to be downregulated (by 2.25­fold [63] compared 
with  2.77­fold  [62])  when  comparing  HIV­infected 
individuals  with  dementia  and  those  without  CNS 
disease. Afamin has been shown to be a specific binding 
protein for vitamin E [64]. The central role of vitamin E, 
which  comprises  eight  related  tocopherols  and  toco­
trienols, is to maintain physiological cellular and tissue 
function  through  the  antioxidant  properties  of  these 
compounds.  Further  analysis  of  α­tocopherol  (αTocH) 
levels  in  the  plasma  samples  of  monkeys  with  SIVE 
revealed decreases, but to varying extents [62]. However, 
an  identical  result  was  found  in  animals  that  did  not 
develop  CNS  disease.  Thus,  the  decrease  in  αTocH 
correlated with infection itself and not the development 
of  CNS  disease,  in  contrast  to  afamin,  which  was 
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disease.
Another potential biomarker was identified from our 
earlier  gene  expression  analysis  on  SIVE  rhesus  brains 
[57].  Osteopontin  (OPN;  also  known  as  secreted 
phospho  protein  1,  SPP1)  is  an  extracellular  protein 
important  in  regulating  differentiation,  immune  cell 
activation  and  cell  attachment  and  migration  [65]. 
Subsequent studies revealed that OPN increased reten­
tion of monocytes and their protection from apoptosis 
[66], suggesting an underlying mechanism of macrophage 
accumulation  during  HIV/SIV  infection.  An  enzyme­
linked  immunosorbent  assay  (ELISA)  revealed  an 
increase of OPN in the CSF of HIV­infected individuals 
[66,67]. However, there was no difference in OPN CSF 
levels  between  HIV­infected  individuals  with  neuro­
cognitive disorders and those without such disorders. In 
plasma, however, ELISA analyses revealed a sequential 
increase in OPN across different diagnostic categories of 
HIV­associated neurocognitive disorders. We also found 
that expression of one of the receptors for OPN, a splice 
variant  form  of  CD44  (CD44v6),  is  increased  at  early 
time points on monocytes in monkeys that will develop 
SIVE [68]. From a therapeutic standpoint, lowering OPN 
levels  or  its  signaling  is  one  possible  strategy  to 
ameliorate neuroAIDS.
Organelle proteomics
Although profiling of biofluids such as CSF and plasma 
have been useful, the ability to analyze the brain itself is 
key. A recent study using classical biochemical fractiona­
tion  isolated  synaptosomes  (a  subcellular  fraction  of 
nerve terminals and the synaptic region) from 19 human 
post­mortem  specimens  from  uninfected  and  HIV­
infected  individuals  classified  by  viral  RNA  load  and 
immunoproteasome  (IPS)  concentrations  as  low  HIV/
low IPS and high HIV/high IPS, of which the latter group 
had  four  individuals  with  HIVE  [69].  Using  two­
dimensional  polyacrylamide  gel  electrophoresis  (2D­
PAGE)  and  matrix­assisted  laser  desorption  ionization 
time­of­flight MS, the authors [69] identified potentially 
functionally  important  alterations  in  synaptic  proteins, 
such as synapsin 1b (SYN1), which was downregulated in 
individuals  with  high  HIV  loads.  SYN1  is  a  phospho­
protein  protein  present  primarily  in  the  presynaptic 
terminals that regulates synaptic vesicle pools bound to 
cytoskeletal  proteins  and  modulates  neurotransmitter 
release in response to a stimulus [70]. The decrease in its 
expression  with  HIV­1  infection  suggests  that  there  is 
abnormal regulation of the reserve pool of vesicles and 
thus  abnormal  neurotransmission.  In  addition,  two 
proteins  belonging  to  the  14­3­3  family  (14­3­3ζ  and 
14­3­3ε),  which  are  crucial  for  regulation  of  neuronal 
processes, including synaptic plasticity, were increased in 
individuals  with  high  HIV  loads.  These  isoforms  have 
been previously reported to be increased in the CSF of 
patients  with  HIV/AIDS,  primarily  those  with  HAD 
[71,72]. The CSF of SIV­infected monkeys also showed 
higher expression of 14­3­3 proteins in animals with CNS 
disease [73].
In  addition,  changes  in  proteasomal  proteins  were 
found [69]. One proteasomal subunit protein, LMP7, was 
increased in individuals with high HIV loads, increasing 
the evidence that disruption of this process is linked to 
HIV­associated  neurodegeneration.  To  determine 
whether the altered synaptosomal proteins in HIV/AIDS 
are  histologically  related  to  immunoproteasomal 
subunits, confocal microscopy was performed, showing 
co­expression of LMP7 and 14­3­3ζ in punctate neuronal 
and  neuropil  markings  in  brains  with  high  HIV  loads 
[69].  Taken  together,  these  findings  [69­72]  reflect 
changes in the synaptodendritic arbor, which have been 
documented during high HIV loads in the brain [74], and 
give important insights into how HIV can affect neurons 
in the brain while not infecting them.
The scope of metabolomics
The use of proteomics to study neuroAIDS has been well 
documented.  Another  high­throughput  methodology, 
meta  bolomics,  quantifies  all  low  molecular  weight 
endogenous  metabolites  in  specified  cellular,  tissue  or 
biofluid compartments and has seen increasing develop­
ment  and  use.  The  measurement  of  metabolites  is 
fundamental to every aspect of biology, from basic bio­
chemistry  to  standard  tests  in  clinical  medicine. 
Although  high­density  data  gathering  metabolomics 
tech  nologies  are  still  under  development,  this 
methodology may soon become superior to other post­
genomic technologies for pattern­recognition analyses of 
biological  samples.  A  recent  review  [75]  describes  the 
translation  of  important  metabolomics  findings  on 
neuro  logical  disorders  to  the  clinic.  Although  early  on 
this  field  centered  around  toxicological  profiling  and 
inborn  errors  of  metabolism,  recent  applications  have 
been  extended  to  biomarker  discovery,  including  for 
neurodegenerative disorders (reviewed in [76]).
Earlier  targeted  studies  had  identified  changes  in 
specific metabolite levels in CSF. For example, quinolinic 
acid,  part  of  the  kynurenine  pathway,  was  shown  to 
increase in CSF during HIV and SIV infection [77,78]. 
Similarly, the nitric oxide metabolites nitrate and nitrite 
were increased in a similar manner in the CSF [26,79,80]. 
Although  these  studies  used  a  directed  approach,  our 
group  has  used  a  global  MS­based  metabolomics 
approach to identify differentially regulated metabolites 
in the CSF of monkeys before and after infection with 
SIV  [81].  We  found  various  metabolites  to  be  up­
regulated, including carnitine, acyl­carnitines, fatty acids 
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molecules [81]. In conjunction with gene array analysis, 
the increase in free fatty acids and lysophospholipids was 
found to correlate with increased expression of specific 
phospholipases,  PLA1A  and  PLA2G4C;  PLA2G4C  can 
release numerous identified fatty acids. Further, in situ 
hybridization experiments revealed increased expression 
of  PLA2G4C  in  monkeys  with  SIVE.  Identification  of 
specific  metabolites  as  well  as  mechanisms  of  their 
increase  greatly  add  to  the  credibility  and  potential  of 
MS­based metabolomics and demonstrates its power to 
identify potential markers for neuroAIDS.
Conclusions
The  potential  of  post­genomic  strategies  has  increased 
immensely  in  recent  years.  In  the  case  of  neuroAIDS, 
proteomics  has  revealed  signs  of  immune  system 
activation and protective responses. These have added to 
the  clues  provided  by  earlier  gene  array  studies  and, 
importantly, they provide molecules that can be assessed 
in  biofluids  in  future  studies.  Proteomics  has  also 
identified  post­translational  modifications  that  affect 
protein  function.  Although  proteins  carry  out  most 
biological events in a cell, the chemical transformations 
catalyzed by enzymes lead to metabolites that themselves 
have  important  physiological  roles.  In  addition  to 
metabolic  functions,  such  metabolic  products  mediate 
crucial  interneuronal  communications  in  the  brain. 
Combining  metabolomics  with  gene  array  studies  in 
neuroAIDS has led to discovery of a pathogenic process: 
phospholipase activation involving an increase in specific 
lipids in the CNS. This helps to illustrate that although 
each  of  these  approaches  is  crucial,  long­term  success 
will most certainly depend on integrating them. Additional 
developments and work in proteomics and metabolomics 
will  enable  a  better  understanding  of  the  physiological 
alterations  leading  to  disease,  as  well  as  providing 
additional  biomarkers  for  diagnosis  and  thera  peutic 
intervention.
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